Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases

2021 ◽  
Author(s):  
Zeynep Oruç ◽  
M. Ali Kaplan ◽  
Mustafa Karaağaç ◽  
Neslihan Özyurt ◽  
Ali Murat Tatlı ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Options ◽  
Hormone Refractory Prostate Cancer ◽  
Line Treatment ◽  
First Line ◽  
Significant Difference ◽  
Visceral Metastases ◽  
Hormone Refractory ◽  
First Line Treatment

Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9–17) months, 6 (95% Cl: 1.8–10.1) months and 11 (95% Cl: 0.9–23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival.

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

2007 ◽  
Vol 52 (4) ◽  
pp. 1020-1027 ◽  
Author(s):  
Giuseppe Di Lorenzo ◽  
Riccardo Autorino ◽  
Sisto Perdonà ◽  
Michele De Laurentiis ◽  
Massimo D'Armiento ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Hormone Refractory Prostate Cancer ◽  
Line Treatment ◽  
First Line ◽  
Hormone Refractory ◽  
First Line Treatment

Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer

2004 ◽  
Vol 46 (6) ◽  
pp. 712-716 ◽  
Author(s):  
Giuseppe Di Lorenzo ◽  
Carmine Pizza ◽  
Riccardo Autorino ◽  
Michele De Laurentiis ◽  
Ombretta Marano ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hormone Refractory Prostate Cancer ◽  
Line Treatment ◽  
First Line ◽  
Weekly Docetaxel ◽  
Hormone Refractory ◽  
First Line Treatment

Vinorelbine plus prednisone versus docetaxel plus prednisone as first-line treatment in metastatic hormone-refractory prostate cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15129-e15129 ◽  
Author(s):  
Inas Ibraheim Abdel Halim ◽  
Wael M El Sadda ◽  
Fatma Farouk ◽  
Esam El Sherbeiny ◽  
Mohamed S El Ashry
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Option ◽  
Similar Efficacy ◽  
Therapeutic Benefit ◽  
Phase Iii ◽  
Hormone Refractory Prostate Cancer ◽  
Line Treatment ◽  
First Line ◽  
Hormone Refractory ◽  
First Line Treatment

e15129 Background: Metastatic hormone refractory prostate cancer (mHRPC) is not curable and all attempts at therapeutic intervention have been based on palliating the disease. Androgen dependent prostate carcinoma responds poorly to chemotherapy. Recent protocols using vinorelbine, mitoxantrone and docetaxel have significantly improved response rate, survival and pain control for those patients. The study aims to compare the therapeutic benefit of the use of vinorelbine versus docetaxel both plus prednisone in patients with mHRPC. Methods: Sixty pts (50% gpA, 50% gpB) were enrolled between Mar 2005 and Sep 2007. All patients had histologically confirmed prostatic adencarcinoma with evidence of metastatic disease and progression on hormonal therapy. WHO PS O-2, adequate marrow, liver and renal functions. Patients were randomized to gpA; Vinorellrine (V) IV 30mg/m2 d1 and 8, or gpB; Docetaxe (D) IV 75mg/m2 d1. All patients received 5mg of prednisone orally twice daily for 5 days starting on day 1 of the tudy. Cycles repeated every 3 weeks. Patients with PD went off the study while those with CR, PR or SD continued treatment for 8 cycles maximum. Results: All pts were evaluable for response, toxicity and survival. The median age (gpA, gpB): 59 and 58 years, median WHO PS 1 (range 0-2) in both groups , Median basal PSA were 110 (90-780) and 120 (80-850) in group A&B respectively. The overall response rates were 53.3% (gpA) and 56.7% (gpB) P=0.24, the rates of PSA decline were higher in gpA than gpB (80% vs 70%) (p=0.27). Reduction of pain was better in patients receiving (V) than those treated with (D) (60% vs 50%) (p= 0.23). The improvement in the quality of life was higher in gp A than in gpB (50% vs 40%) but the difference was statistically insignificant. No WHO G3 or 4 toxicities in gp A. G3 alopecia (60%), G3 neutropenia (20%) were noted in gpB. Conclusions: Our results suggest that vinorelbine and docetaxel demonstrate similar efficacy as first line treatment for mHRPC. Vinorelbine is however better tolerated besides being a less costly therapeutic option in Egypt. Comparative phase III trial is needed to confirm these results.

scholarly journals A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Winnie W. Y. Sung ◽  
Horace C. W. Choi ◽  
Peter H. Y. Luk ◽  
Tsz Him So
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Lifetime Cost ◽  
Treatment Options ◽  
Sensitivity Analyses ◽  
Line Treatment ◽  
First Line ◽  
Life Years ◽  
Hormone Sensitive ◽  
First Line Treatment

BackgroundCurrently, approved first-line treatment options of metastatic hormone-sensitive prostate cancer (mHSPC) include (1) androgen deprivation therapy (ADT) alone, ADT plus one of the following: (2) docetaxel, (3) abiraterone, (4) enzalutamide, and (5) apalutamide. The high cost of novel androgen receptor pathway inhibitors warrants an understanding of the combinations’ value by considering both efficacy and cost.ObjectiveThis study aimed to compare the cost-effectiveness of these five treatment options in mHSPC from the US payer perspective to guide treatment sequence.MethodsA Markov model was developed to compare the lifetime cost and effectiveness of these five first-line treatment options for mHSPC using outcomes data from published literature. Health outcomes were measured in life-years and quality-adjusted life-years (QALYs). Drug costs were obtained from the Veterans Affairs Pharmaceutical Catalog. We extrapolated survival beyond closure of the trials.Outcome Measurements and Statistical AnalysisLife-years, QALYs, lifetime costs, and incremental cost-effectiveness ratios (ICERs) were estimated. Univariable, 2-way, and probabilistic sensitivity analyses were performed to evaluate parameter uncertainty. A willingness-to-pay (WTP) threshold of US$100,000 per QALY was used.ResultsCompared to ADT alone, docetaxel plus ADT provided a 0.28 QALY gain at an ICER of US$12,870 per QALY. Abiraterone plus ADT provided an additional 1.70 QALYs against docetaxel plus ADT, with an ICER of US$38,897 per QALY. Compared to abiraterone plus ADT, enzalutamide plus ADT provided an additional 0.87 QALYs at an ICER of US$509,813 per QALY. Apalutamide plus ADT was strongly dominated by enzalutamide plus ADT. Given the WTP threshold of US$100,000 per QALY, abiraterone plus ADT represented high-value health care.ConclusionsAbiraterone plus ADT is the preferred treatment option for men with mHSPC at a WTP threshold of US$100,000 per QALY.

Survey on management of metastatic hormone-refractory prostate cancer upon progression during or following first-line chemotherapy in five European countries.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15198-e15198
Author(s):  
Sebastien Auziere ◽  
Alain Flinois ◽  
Eliot Obi-Tabot ◽  
Mathieu Rose ◽  
Adam Parnaby
Keyword(s):  
Prostate Cancer ◽  
Representative Sample ◽  
Treatment Options ◽  
European Countries ◽  
Hormone Refractory Prostate Cancer ◽  
Chemotherapy Treatment ◽  
First Line ◽  
Chemotherapy Agent ◽  
Hormone Refractory ◽  
Line Chemotherapy

e15198 Background: In Europe, docetaxel is the standard first-line chemotherapy (1L) for patients with metastatic hormone-refractory prostate cancer (mHRPC). Upon progression, either during or after 1L chemotherapy, treatment options are limited. This study evaluated how patients who progressed during or after 1L docetaxel between Oct 2009 and Jun 2010 were managed. Methods: A representative sample of 349 physicians (oncologists, urologists) who managed patients with mHRPC selected from Germany, France, UK, Spain and Italy were surveyed. Information on the treatments used at the time of progression (during or within the first 6 months following 1L treatment with docetaxel was provided. Results: Information on a total of 2,870 mHRPC patients was provided of which 2,670 (94 %) had received docetaxel in 1L. 1,389 (52%) patients progressed during 1L docetaxel or within 6 months following treatment; of these, 615 (44 %) received as 2L chemotherapy (Table). Conclusions: In this study, mitoxantrone was the most commonly used chemotherapy agent for 2L treatment of patients with mHRPC who progressed during treatment or within the first 6 months following the end of 1L. Docetaxel rechallenge was uncommon for patients experiencing progression early, during or after the end of 1L. [Table: see text]

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

2015 ◽  
Vol 11 (6) ◽  
pp. 965-973 ◽  
Author(s):  
Orazio Caffo ◽  
Giovanni Lo Re ◽  
Teodoro Sava ◽  
Sebastiano Buti ◽  
Cosimo Sacco ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Line Treatment ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant ◽  
Docetaxel Chemotherapy ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document